What should be done about Health Canada?

Submitted by Carlyn Zwarenstein on September 29, 2014 - 11:38

This weekend the Toronto Star published a thought-provoking op-ed arguing that in the light of Health Canada's incompetence or outright neglect (summed up pretty well in an editorial published today in the same paper) in failing to demand that Apotex pull tainted or poor quality drugs off their shelves--along with other failures to p

Side-effects reporting for drug trials + more

Submitted by Carlyn Zwarenstein on September 16, 2014 - 12:00

Over the years, Open Medicine authors have taken a strong interest in research ethics and particularly the dangers of overly-close or conflicted relationships with pharmaceutical and medical device companies. As you may have intuited from the "closed for submissions" notice on our home page, for a variety of reasons Open Medicine is going to be closing up shop over the next couple of months.

Drug safety in the news

Submitted by Carlyn Zwarenstein on September 11, 2014 - 22:34

We've looked at the issue of drug safety from different angles through various Open Medicine papers. Never this one though. In today's Toronto Star. 

Funding systems and what gets funded

Submitted by Carlyn Zwarenstein on September 5, 2014 - 17:01

So, IS there a creativity deficit in science? If there is, what's causing it? This article by scientist Ben McNeil looks at publish-or-perish, the problem with preliminary data, risk-averse funding, the age bias and lots more. Definitely worth checking out.

Getting medical marijuana laws right

Submitted by Carlyn Zwarenstein on July 25, 2014 - 21:47

An interesting piece today relating to Canada's evolving laws on medical marijuana.

CBC News on Joep Lange, triple therapy for HIV, and Dr. Lange''s links to the Canadian research community

Submitted by Carlyn Zwarenstein on July 21, 2014 - 15:34

"If we can get cold Coca–Cola and beer to every remote corner of Africa, it should not be impossible to do the same with drugs."

More on Joep Lange, who died on Malaysia Airlines Flight MH17:


Healthcare system woes

Submitted by Carlyn Zwarenstein on July 18, 2014 - 13:12

A recent report from the Commonwealth Fund, a non-profit, private American foundation, compares the U.S. healthcare system with a number of its international counterparts.

Drug development in the sharing economy

Submitted by Carlyn Zwarenstein on June 23, 2014 - 13:55

Sharing—what a concept. With scientific research tending in two directions—on one hand, towards more proprietary knowledge and more expensive and limited access, and on the other, towards open data and open access publications—it is interesting to note a new private-public partnership based in Toronto and New York that will provide completely open access to anyone who wants to use its structural genomics data. Is this what real sharing of information should look like?

Media release: Guide to noninferiority trials for novel therapies

Submitted by Carlyn Zwarenstein on May 6, 2014 - 06:42

A clinician’s guide to the assessment and interpretation of noninferiority trials for novel therapies

Open Medicine
A peer-reviewed, independent, open-access journal.


Open Access is for patients too.

Submitted by Carlyn Zwarenstein on April 30, 2014 - 21:17

A flurry of study on the topic of open access--always, of course, of special interest around here--as I prepare a talk for a festival of arts and science in Toronto (more on that, to come), on the experience our journal has had with open access from shortly after the concept itself was developed and named. I am coming across all sorts of fascinating things in the process.